Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
And then I couldn't stand
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile
BENEFITS Light, water-gel formula Proven to visibly reduce surface shine and congestion in 2 weeks Minimizes excess sebum with daily use, while providing optimal hydration Reduces visible redness for a more uniform complexion Reduces the appearance of large pores Fragrance- and alcohol-free Removes excess surface oil and pore-clogging debris
Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC
Week A Day 1: 500mg NAD IV ( 2-3.5 hrs) Day 4: 100mg NAD SQ Day 6: 100mg NAD SQ Daily: 500mg NR/NMN in the morning Week B Daily: 500mg NR/NMN in the morning Day 1: 100mg NAD SQ Day 4: 100mg NAD SQ Day 6: 100mg NAD SQ Use this cycle and keep repeating, modifying it as you see fit
Sometimes used as an off-label medication for weight loss, this is not an approved GLP-1 for weight loss
